Navigation Links
MIT research holds promise for Huntington's treatment

Researchers at MIT and Harvard Medical School have identified a compound that interferes with the pathogenic effects of Huntington's disease, a discovery that could lead to development of a new treatment for the disease.

There is no cure for Huntington's, a neurodegenerative disorder that now afflicts 30,000 Americans, with another 150,000 at risk. The fatal disease, which is genetically inherited, usually strikes in midlife and causes uncontrolled movements, loss of cognitive function and emotional disturbance.

"There are now some drugs that can help with the symptoms, but we can't stop the course of the disease or its onset," said Ruth Bodner, lead author on a paper appearing online the week of Mar. 6 in the Proceedings of the National Academy of Sciences (PNAS). Bodner is a postdoctoral fellow in MIT's Center for Cancer Research.

The compound developed by Bodner and others in the laboratories of MIT Professor of Biology David Housman, Harvard Medical School Assistant Professor Aleksey Kazantsev and Harvard Medical School Professor Bradley Hyman might lead to a drug that could help stop the deadly sequence of cellular events that Huntington's unleashes.

"Depending on its target, any one compound will probably block only a subset of the pathogenic effects," Bodner said.

Huntington's disease is caused by misfolded proteins, called huntingtin proteins, that aggregate and eventually form large clump-like "inclusions." The disease is characterized by degeneration in the striatum, an area associated with motor and learning functions, and the cortex. The proteins may disrupt the function of cellular structures known as proteasomes, which perform a "trash can" function for the cell -- disposing of cellular proteins that are misfolded or no longer needed, said Bodner.

Without a functional proteasome, those cellular proteins accumulate, poisoning brain cells and impairing patients' motor and cognitive function.

Until
'"/>

Source:Massachusetts Institute of Technology


Page: 1 2

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
Other Biology Technology:Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company 2Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company 3Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company 4Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company 5Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company 6Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company 7Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company 8Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company 9Health Experts Call for New Strategies to Combat Alarming Rise in Diabetes 2Health Experts Call for New Strategies to Combat Alarming Rise in Diabetes 3Health Experts Call for New Strategies to Combat Alarming Rise in Diabetes 4BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors 2